ライフサイエンスコーパス: cromolyn

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 mast cell stabilizer' disodium cromoglycate (cromolyn).

2 EIA for up to 3 h and is more effective than cromolyn.

3 out preincubation with luteolin, methlut, or cromolyn (1-100 mumol/L) for 2 or 24 hours, after which

4 nhaled 4 ml of either heparin (20,000 u/ml), cromolyn (20 mg), or placebo solutions with increasing p

5 ded albuterol (81%), inhaled steroids (38%), cromolyn (35%), and theophylline (23%).

6 Cromolyn, a mast cell stabilizer, injected centrally 1 h

7 Cromolyn, a mast cell stabilizer, reduced BALF cells and

8 Prevention of mast cell degranulation with cromolyn, ablation of visceral afferents with capsaicin,

9 Other anti-inflammatory agents such as cromolyn and the new class of leukotriene receptor antag

10 ndition became resistant to corticosteroids, cromolyn, and intravenous gamma globulin.

11 ough heparin offered greater protection than cromolyn (at 1 to 3 h), both agents were ineffective whe

12 1 h and 3 h, respectively, before exercise; cromolyn attenuated the responses by 37%, 46%, and 41%,

13 LIGRL-NH(2); this effect was not observed in cromolyn-, capsaicin-, or RP67580-treated rats but was d

14 Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbat

15 y of the antiasthma and antiallergic ligands cromolyn disodium and nedocromil sodium, we identified t

16 is a more potent inhibitor than luteolin or cromolyn for beta-hexosaminidase and histamine secretion

17 Heparin and cromolyn had no effect on baseline SGaw but attenuated t

18 rt by 40% to 85%, whereas prostaglandins and cromolyn had no effect.

19 However, neither the treatment with cromolyn nor the deficiency of mast cells (WBB6F1-Kit(W/

20 Mast cell stabilization with cromolyn or lodoxamide markedly reduced active renin ove

21 that interfere with histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spantide).

22 Although the effects of pyrilamine, cromolyn, or aprepitant on ET-induced vascular leakage s

23 Here we demonstrate that cromolyn sodium (disodium cromoglycate), a Food and Drug

24 Treatment with cromolyn sodium decreased biliary proliferation, fibrosi

25 Cromolyn sodium effectively stabilized mast cells, yet i

26 knockout mice (9-11 weeks) were treated with cromolyn sodium for 1 week to block MC-derived histamine

27 d mice treated with the MC stabilizing agent cromolyn sodium had dramatically reduced Th2 priming and

28 Pretreatment with the mast cell stabilizer cromolyn sodium improved analgesia following low doses o

29 ation of the potential long-term efficacy of cromolyn sodium in Alzheimer disease.

30 Furthermore, cromolyn sodium treatment was associated with reduced in

31 f inhaled heparin in EIA and compare it with cromolyn sodium, a mast cell stabilizing agent with esta

32 ns have been used including corticosteroids, cromolyn sodium, and leukotriene inhibitors.

33 ls pretreated with the mast cell stabilizer, cromolyn sodium, mast cell degranulation was blocked, an

34 In mice treated with cromolyn sodium, MC infiltration and tumor growth decrea

35 pression that decreased with pretreatment of cromolyn sodium.

36 amine, histidine decarboxylase inhibitor, or cromolyn sodium.

37 ) markers were measured in mice treated with cromolyn sodium.

38 week of daily intraperitoneally administered cromolyn sodium.

39 mpared H1 - and H2 -antihistamines with oral cromolyn sodium.

40 olone acetonide at the ulcer margin; topical cromolyn sodium; oral dapsone, prednisone, cyclosporine,

41 activity (P<0.05), after 8 weeks of topical cromolyn treatment.

42 Cromolyn was similarly associated with reduced risk, esp

43 lyp/lyp rats with the mast cell "stabilizer" cromolyn, which significantly (p < 0.05) delayed T1DM on

44 osed to beta agonists or xanthines (0.8%) or cromolyn without steroids (0.1%).

45 ormal birthweight and full-term infants, the cromolyn without steroids group had the greatest decline

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。